Plain-English translation of NCT07620314 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing , a new type of cell therapy for people with B-cell non-Hodgkin's lymphoma whose cancer has come back or stopped responding to standard treatments. The medication works by using your own immune cells and modifying them in a special way to help them fight cancer cells. Researchers are studying how safe this treatment is and how well it works.
Many patients with this type of blood cancer eventually stop responding to standard chemotherapy treatments, leaving them with limited options. This medication offers a different approach by reprogramming the body's own immune system to target cancer cells, which may help patients whose cancers have become resistant to conventional therapy.
You likely qualify if…
You likely don't qualify if…
If you qualify and enroll, you will receive the medication as an intravenous infusion (injection through your vein). The trial will carefully monitor your safety and how your body responds over time with blood tests, scans, and doctor visits. This is a dose-escalation study, meaning the researchers will start with a lower dose and carefully increase it while watching for side effects, so your treatment plan may depend on how earlier participants respond.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
China